Next Article in Journal
Cardiovascular Magnetic Resonance for Visualization of Myocardial Ischemia at Rest
Previous Article in Journal
Skeletal Muscle-Derived Stem Cells: Implications for Cell-Mediated Therapies
Medicina is published by MDPI from Volume 54 Issue 1 (2018). Articles in this Issue were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence. Articles are hosted by MDPI on as a courtesy and upon agreement with Lithuanian Medical Association, Lithuanian University of Health Sciences, and Vilnius University.
Open AccessArticle

Targeted Therapy in Patients With Non–small Cell Lung Cancer Previously Treated With Chemotherapy

Radiotherapy and Drug Therapy Center, Institute of Oncology, Vilnius University
Diagnostic Radiology Department, Institute of Oncology, Vilnius University, Lithuania
Author to whom correspondence should be addressed.
Medicina 2011, 47(9), 520;
Received: 7 September 2010 / Accepted: 30 September 2011 / Published: 5 October 2011
A case of successful and prolonged treatment of metastatic non–small cell lung cancer with the epidermal growth factor receptor antagonist erlotinib is presented. A never-smoker female was diagnosed with stage IV lung cancer in December 2005. A chest CT scan showed soft tissue mass 35×34 mm in size in the right lung with metastases in the lymph nodes and in the left lung. A biopsy revealed a poorly differentiated adenocarcinoma. The disease showed poor response to the first-line and second-line chemotherapy. Targeted therapy with erlotinib was started in February 2007. The most severe adverse event observed was grade 3 skin rash. The disease was stable until February 2009 when brain metastases were detected. Erlotinib was continued until May 2009 when disease progression in the lungs was confi rmed. The patient died due to ongoing disease progression in December 2009. Retrospective genetic analysis of a tumor specimen was performed, and no mutations in EGFR exons 18–21 were detected. The patient had a significant clinical benefit for the period of 24 months. These results are consistent with previous reports in literature that clinical characteristics such as female gender, nonsmoker, adenocarcinoma histology, and severe cutaneous toxicity seem to predict good response to erlotinib. In the present case, erlotinib proved to be effective even in heavily pretreated, chemotherapy- resistant lung adenocarcinoma. So far, no exact predictive biomarkers of erlotinib effectiveness have been determined; and their further analyses are essential.
Keywords: lung adenocarcinoma; targeted therapy; erlotinib lung adenocarcinoma; targeted therapy; erlotinib
MDPI and ACS Style

Drobnienė, M.; Cicėnienė, A.; Želvienė, T.P.; Grigienė, R.; Lachej, N.; Steponavičienė, L.; Aleknavičius, E. Targeted Therapy in Patients With Non–small Cell Lung Cancer Previously Treated With Chemotherapy. Medicina 2011, 47, 520.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop